← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Praeventix, Llc
Exton, PA
$8,106,462
Total funding
6
Grants
Funding over time
peak $2.5M · FY2017–24$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,106,462 · 6
By mechanism
R44$7,249,117 · 3
R43$857,345 · 3
Investigators at Praeventix, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder$1,250,000
R44 · FY2024 · DA
In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder$1,250,000
R44 · FY2023 · DA
IND Enabling Studies for the Development of Pruritus Therapeutic PRA-523$1,244,708
R44 · FY2023 · AR
Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease$1,228,145
R44 · FY2019 · DK
Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease$1,228,145
R44 · FY2018 · DK
IND Enabling Studies for the Development of Pruritus Therapeutic PRA-523$728,119
R44 · FY2024 · AR
In vivo Characterization of PRA078C in the Rat Cocaine Reinstatement Model$350,000
R43 · FY2019 · DA
In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder$320,000
R44 · FY2022 · DA
Novel 5-HT7 Antagonists for the Treatment of Pruritus$275,544
R43 · FY2022 · AR
Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease$231,801
R43 · FY2017 · DK